Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Gemcitabine|DRUG: Epirubicin|DRUG: Docetaxel
Sponsor: SCRI Development Innovations, LLC
Collaborators: Pharmacia and Upjohn|Eli Lilly and Company|Aventis Pharmaceuticals